TY - JOUR
T1 - Review article
T2 - diagnosis, management and patient perspectives of the spectrum of constipation disorders
AU - Sharma, Amol
AU - Rao, Satish S.C.
AU - Kearns, Kimberly
AU - Orleck, Kimberly D.
AU - Waldman, Scott A.
N1 - Funding Information:
The writing and preparation of this manuscript was funded by Salix Pharmaceuticals, Inc (Bridgewater, NJ, USA). SAW is supported by the National Institute of Health (1R01 CA204881, 1R01 CA206026, P30 CA56036), Department of Defense Congressionally Directed Medical Research Program W81XWH-17-PRCRP-TTSA, The Courtney Ann Diacont Memorial Foundation and Targeted Diagnostic & Therapeutics, Inc. The authors thank Blair Hesp, PhD, CMPP, Julie O'Grady, BA, and Nicole Coolbaugh, CMPP, of The Medicine Group, LLC (New Hope, PA, USA), who provided medical writing and editorial assistance, which was funded by Salix Pharmaceuticals, Inc, in accordance with Good Publication Practice guidelines. Declaration of personal interests: Dr. A. Sharma served on advisory boards for Ironwood Pharmaceuticals, Phathom Pharmaceuticals and Salix Pharmaceuticals. Dr. S. S. C. Rao has served on the advisory board for Medtronic, Takeda Pharmaceuticals and Salix Pharmaceuticals. K. Kearns has served as a speaker for Medtronic and Takeda Pharmaceuticals, and a speaker and advisory board member for Salix Pharmaceuticals. K. D. Orleck has served as a speaker for AbbVie Pharmaceuticals, Allergan Pharmaceuticals and Salix Pharmaceuticals. Dr. S. A. Waldman has served on advisory boards for Salix Pharmaceuticals. He serves on the Board of Directors and is Chair of the Scientific Advisory Board for Targeted Diagnostics & Therapeutics, Inc.
Funding Information:
The writing and preparation of this manuscript was funded by Salix Pharmaceuticals, Inc (Bridgewater, NJ, USA). SAW is supported by the National Institute of Health (1R01 CA204881, 1R01 CA206026, P30 CA56036), Department of Defense Congressionally Directed Medical Research Program W81XWH‐17‐PRCRP‐TTSA, The Courtney Ann Diacont Memorial Foundation and Targeted Diagnostic & Therapeutics, Inc.
Publisher Copyright:
© 2021 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
PY - 2021/6
Y1 - 2021/6
N2 - Background: Chronic constipation is a common, heterogeneous disorder with multiple symptoms and pathophysiological mechanisms. Patients are often referred to a gastroenterology provider after laxatives fail. However, there is limited knowledge of the spectrum and management of constipation disorders. Aim: To discuss the latest understanding of the spectrum of constipation disorders, tools for identifying a pathophysiologic-based diagnosis in the specialist setting, treatment options and the patient's perspective of constipation. Methods: Literature searches were conducted using PubMed for constipation diagnostic criteria, diagnostic tools and approved treatments. The authors provided insight from their own practices. Results: Clinical assessment, stool diaries and Rome IV diagnostic criteria can facilitate diagnosis, evaluate severity and distinguish between IBS with constipation, chronic idiopathic constipation and dyssynergic defecation. Novel smartphone applications can help track constipation symptoms. Rectal examinations, anorectal manometry and balloon expulsion, assessments of neuromuscular function with colonic transit time and colonic manometry can provide mechanistic understanding of underlying pathophysiology. Treatments include lifestyle and diet changes, biofeedback therapy and pharmacological agents. Several classes of laxatives, as well as prokinetic and prosecretory agents, are available; here we describe their mechanisms of action, efficacy and side effects. Conclusions: Constipation includes multiple overlapping subtypes identifiable using detailed history, current diagnostic tools and smartphone applications. Recognition of individual subtype(s) could pave the way for optimal, evidence-based treatments by a gastroenterology provider.
AB - Background: Chronic constipation is a common, heterogeneous disorder with multiple symptoms and pathophysiological mechanisms. Patients are often referred to a gastroenterology provider after laxatives fail. However, there is limited knowledge of the spectrum and management of constipation disorders. Aim: To discuss the latest understanding of the spectrum of constipation disorders, tools for identifying a pathophysiologic-based diagnosis in the specialist setting, treatment options and the patient's perspective of constipation. Methods: Literature searches were conducted using PubMed for constipation diagnostic criteria, diagnostic tools and approved treatments. The authors provided insight from their own practices. Results: Clinical assessment, stool diaries and Rome IV diagnostic criteria can facilitate diagnosis, evaluate severity and distinguish between IBS with constipation, chronic idiopathic constipation and dyssynergic defecation. Novel smartphone applications can help track constipation symptoms. Rectal examinations, anorectal manometry and balloon expulsion, assessments of neuromuscular function with colonic transit time and colonic manometry can provide mechanistic understanding of underlying pathophysiology. Treatments include lifestyle and diet changes, biofeedback therapy and pharmacological agents. Several classes of laxatives, as well as prokinetic and prosecretory agents, are available; here we describe their mechanisms of action, efficacy and side effects. Conclusions: Constipation includes multiple overlapping subtypes identifiable using detailed history, current diagnostic tools and smartphone applications. Recognition of individual subtype(s) could pave the way for optimal, evidence-based treatments by a gastroenterology provider.
UR - http://www.scopus.com/inward/record.url?scp=85106603981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106603981&partnerID=8YFLogxK
U2 - 10.1111/apt.16369
DO - 10.1111/apt.16369
M3 - Review article
C2 - 33909919
AN - SCOPUS:85106603981
SN - 0269-2813
VL - 53
SP - 1250
EP - 1267
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 12
ER -